Keyword: Merck & Co.

Initial lab work suggests that the Ebola Zaire strain—the one targeted by Merck's rVSV-ZEBOV—is likely the cause of this outbreak.

Merck & Co. likely expected big numbers when it agreed to fork over $5.8 billion to share rights to Eisai's Lenvima. And those numbers are rolling in.

French drugmaker Sanofi has confirmed some of its manufacturing facilities are stockpiling key meds ahead of next year's Brexit separation.

AbbVie is hitting the road this month to spur veterans toward hepatitis C testing in a cross-country bus tour with the American Legion.

Merck's HPV shot, Gardasil, continued to gain steam in the second quarter, and execs see "significant" growth prospects ahead.

Merck’s Keytruda is one step closer to extending its dominance in the all-important previously untreated lung cancer market.

Excluding ALK and EGFR, about two-thirds of new NSCLC patients are now starting their treatment with Keytruda, said an executive.

Eisai and Biogen's recent Alzheimer's data spark debate; Beijing works to contain a vaccine scandal; BMS and Tsinghua University pen drug discovery pact.

Celgene is extracting volume-driven sales growth as the entire industry has come under scrutiny for its pricing.

Merck’s Keytruda may just be on its way to earlier use in head and neck cancer, an area where it once faced some questions.